Change in Management

Lavino is deemed to be very experienced. He has worked for pharmaceutical and biotech companies for more than twenty years. Before joining F2G, he was Chief Commercial Officer at Nabriva Therapeutics, where he led the development of the commercial organisation in the US. He spent nearly 15 years at Merck and Cubist Pharmaceuticals in various commercial roles and therapeutic areas.

The new F2G CEO will based in Princeton, New Jersey (USA). He will lead the development and commercialization of olorofim. The antifungal agent got two Breakthrough Therapy Designations from the FDA: for the indication of "Treatment of Central Nervous System (CNS) coccidioidomycosis refractory or otherwise unable to be treated with standard of care therapy" and for "Treatment of invasive mold infections in patients with limited or no treatment options, including aspergillosis refractory or intolerant to currently available therapy, and infections due to Lomentospora prolificans, Scedosporium, and Scopulariopsis species".

After eight years as CEO, Ian Nicholson stepped down to take over non-executive responsibilities. But, he will continue to provide support to ensure an effective transition.